Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
Add more filters










Publication year range
1.
Oncotarget ; 9(77): 34554-34566, 2018 Oct 02.
Article in English | MEDLINE | ID: mdl-30349649

ABSTRACT

PURPOSE: The identification of genes with synthetic lethality in the context of mutant TP53 is a promising strategy for the treatment of basal-like triple negative breast cancer (TNBC). This study investigated regulators of mutant TP53 (R248Q) in basal-like TNBC and their impact on tumorigenesis. EXPERIMENTAL DESIGN: TNBC cells were analyzed by RNA-seq, and synthetic-lethal shRNA knock-down screening, to identify genes related to the expression of mutant TP53. A tissue microarray of 232 breast cancer samples, that included 66 TNBC cases, was used to assess clinicopathological correlates of tumor protein expression. Functional assays were performed in vitro and in vivo to assess the role of ADORA2B in TNBC. RESULTS: Transcriptome profiling identified ADORA2B as up-regulated in basal-like TNBC cell lines with R248Q-mutated TP53, with shRNA-screening suggesting the potential for a synthetic-lethal interaction between these genes. In clinical samples, ADORA2B was highly expressed in 39.4% (26/66) of TNBC patients. ADORA2B-expression was significantly correlated with ER (P < 0.01), PgR (P = 0.027), EGFR (P < 0.01), and tumor size (P = 0.037), and was an independent prognostic factor for outcome (P = 0.036). In line with this, ADORA2B-transduced TNBC cells showed increased tumorigenesis, and ADORA2B knockdown, along with mutant p53 knockdown, decreased metastasis both in vitro and in vivo. Notably, the cytotoxic cyclic peptide SA-I suppressed ADORA2B expression and tumorigenesis in TNBC cell lines. CONCLUSIONS: ADORA2B expression increases the oncogenic potential of basal-like TNBC and is an independent factor for poor outcome. These data suggest that ADORA2B could serve as a prognostic biomarker and a potential therapeutic target for basal-like TNBC.

2.
Anticancer Res ; 37(5): 2425-2436, 2017 05.
Article in English | MEDLINE | ID: mdl-28476810

ABSTRACT

BACKGROUND: NSC697923, a ubiquitin-conjugating enzyme E2 (UBE2) inhibitor, was suggested as an agent to degrade hypoxia-inducible factor 1 alpha subunit (HIF1α), a key factor in radiation resistance. We attempted to clarify whether NSC697923 could overcome radiation resistance. MATERIALS AND METHODS: Radiation resistance and expression of HIFs were evaluated in radiation-sensitive HCT116 and -resistant SW480 cells treated with or without NSC697923 and radiation under normoxia and hypoxia in vitro and in vivo. We examined NSC697923-regulated genes using RNA sequencing. RESULTS: HIF expression significantly increased under hypoxia with an increase of cellular radiation resistance in vitro and in vivo. The therapeutic activity of NSC697923 was higher in radiation-resistant SW480 than radiation-sensitive HCT116 in vivo. Next-generation RNA sequencing revealed that NSC697923 regulated the expression of cell migration-inducing protein, hyaluronan binding (CEMIP) and apelin (APLN) genes, that are related to HIF pathways. CONCLUSION: NSC697923 might effectively regulate HIF families, and be a promising partner with radiation to overcome resistance.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/antagonists & inhibitors , Hypoxia-Inducible Factor 1, alpha Subunit/antagonists & inhibitors , Nitrofurans/pharmacology , Nitrofurans/therapeutic use , Radiation Tolerance/drug effects , Sulfones/pharmacology , Sulfones/therapeutic use , Ubiquitin-Conjugating Enzymes/antagonists & inhibitors , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Cell Hypoxia/drug effects , Cell Hypoxia/genetics , Cell Line, Tumor , Cell Survival/drug effects , Cisplatin/pharmacology , Cisplatin/therapeutic use , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Colorectal Neoplasms/radiotherapy , Gene Expression Regulation, Neoplastic/drug effects , Humans , Male , Mice, Inbred BALB C , Mice, Nude , Tumor Burden/radiation effects
3.
Clin Cancer Res ; 23(13): 3442-3452, 2017 07 01.
Article in English | MEDLINE | ID: mdl-28087642

ABSTRACT

Purpose: Expression of the ΔN isoform of p63 (ΔNp63) is a diagnostic marker highly specific for lung squamous cell carcinoma (SCC). We previously found that Syntaxin Binding Protein 4 (STXBP4) regulates ΔNp63 ubiquitination, suggesting that STXBP4 may also be an SCC biomarker. To address this issue, we investigated the role of STXBP4 expression in SCC biology and the impact of STXBP4 expression on SCC prognosis.Experimental Design: We carried out a clinicopathologic analysis of STXBP4 expression in 87 lung SCC patients. Whole transcriptome analysis using RNA-seq was performed in STXBP4-positive and STXBP4-negative tumors of lung SCC. Soft-agar assay and xenograft assay were performed using overexpressing or knockdown SCC cells.Results: Significantly higher levels of STXBP4 expression were correlated with accumulations of ΔNp63 in clinical lung SCC specimens (Spearman rank correlation ρ = 0.219). Notably, STXBP4-positive tumors correlated with three important clinical parameters: T factor (P < 0.001), disease stage (P = 0.030), and pleural involvement (P = 0.028). Whole transcriptome sequencing followed by pathway analysis indicated that STXBP4 is involved in functional gene networks that regulate cell growth, proliferation, cell death, and survival in cancer. Platelet-derived growth factor receptor alpha (PDGFRα) was a key downstream mediator of STXBP4 function. In line with this, shRNA mediated STXBP4 and PDGFRA knockdown suppressed tumor growth in soft-agar and xenograft assays.Conclusions: STXBP4 plays a crucial role in driving SCC growth and is an independent prognostic factor for predicting worse outcome in lung SCC. These data suggest that STXBP4 is a relevant therapeutic target for patients with lung SCC. Clin Cancer Res; 23(13); 3442-52. ©2017 AACR.


Subject(s)
Carcinoma, Squamous Cell/genetics , Lung Neoplasms/genetics , Receptor, Platelet-Derived Growth Factor alpha/genetics , Vesicular Transport Proteins/genetics , Adult , Aged , Aged, 80 and over , Animals , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Cell Proliferation/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Lung Neoplasms/pathology , Male , Mice , Middle Aged , Prognosis , Signal Transduction/genetics , Xenograft Model Antitumor Assays
4.
Breast Cancer ; 23(5): 780-8, 2016 Sep.
Article in English | MEDLINE | ID: mdl-26476745

ABSTRACT

BACKGROUND: The members of AID/APOBEC protein family possess cytidine deaminase activity that converts cytidine residue to uridine on DNA and RNA. Recent studies have shown the possible influence of APOBEC3B (A3B) as DNA mutators of breast cancer genome. However, the clinical significance of A3B expression in Japanese breast cancer has not been studied in detail. METHODS: Ninety-three primary breast cancer tissues (74 estrogen-receptor (ER) positive, 3 ER and HER2 positive, 6 HER2 positive, and 10 triple negative) including 37 tumor-normal pairs were assessed for A3B mRNA expression using quantitative real-time RT-PCR. We analyzed the relation between A3B expression, mutation analysis of TP53 and PIK3CA by direct sequencing, polymorphic A3B deletion allele and human papillomavirus (HPV) infection in tumors. RESULTS: A3B mRNA was overexpressed in tumors compared with normal tissue. Patients with high A3B expression were associated with subtype and progression of lymph node metastasis and pathological nuclear grade. However, the expression was not related to any other clinicopathological factors, including mutation of TP53 and PIK3CA, polymorphic A3B deletion allele, HPV infection and survival time. CONCLUSION: The expression of A3B in breast cancer was higher than in non-cancerous tissues and was related to the lymph node metastasis and nuclear grade, which are reliable aggressive phenotype markers in breast cancer. Evaluation of A3B expression in tumor may be a marker for breast cancer with malignant potential.


Subject(s)
Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cytidine Deaminase/genetics , Gene Expression Regulation, Neoplastic , Minor Histocompatibility Antigens/genetics , Adult , Aged , Asian People , Breast Neoplasms/mortality , Class I Phosphatidylinositol 3-Kinases , Cohort Studies , Female , Humans , Kaplan-Meier Estimate , Lymphatic Metastasis/genetics , Middle Aged , Mutation , Phosphatidylinositol 3-Kinases/genetics , Tumor Suppressor Protein p53/genetics
5.
Atherosclerosis ; 237(2): 464-70, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25463075

ABSTRACT

OBJECTIVE: Cigarette smoking is a known risk factor for arteriosclerosis. In atheromatous plaques, vascular smooth muscle cells (VSMCs) display a phenotype that is different from the contractile type under normal conditions. Nicotine is the major pharmacological agent in cigarette smoke. However, any direct effect of nicotine on VSMCs remains uncertain. Because nicotine promotes VSMC migration, its phenotype may change due to nicotine. APPROACH AND RESULTS: We used human aorta primary smooth muscle cells (HuAoSMCs), differentiated with transforming growth factor-ß, to investigate changes in the protein levels of differentiation markers and in the activity of mitogen-activated protein kinases (MAPKs) after exposure to 0.1 µM of nicotine for 48 h. After nicotine exposure, the protein levels of myosin II 10 (2.93-fold) and ß-actin (1.66-fold), synthetic type markers, were increased. In contrast, the levels of the contractile type markers, myosin II 11 (0.63-fold), high-molecular-weight caldesmon (0.40-fold) and SM22 (0.66-fold), which concern differentiated VSMC, were decreased. Moreover, nicotine exposure induced enhanced activation of p38 MAPK (1.30-fold) and extracellular signal-regulated kinase (1.91-fold). These results indicated that the phenotype of HuAoSMCs had changed to a synthetic-like type because of nicotine exposure. Thus, nicotine is one factor that can alter protein expression of differentiation markers in VSMCs. Besides, the increase of intracellular Ca(2+) levels suggested that these effects of nicotine were mediated through nicotinic acetylcholine receptors. CONCLUSION: Nicotine has already been reported to promote VSMC migration from the tunica media to atheromatous plaques in the vascular intima. This phenomenon may occur because nicotine directly induces VSMC transformation from contractile type to synthetic-like type via nicotinic acetylcholine receptors and G protein-coupled receptors.


Subject(s)
Aorta/cytology , Muscle Contraction/drug effects , Muscle, Smooth, Vascular/cytology , Myocytes, Smooth Muscle/drug effects , Nicotine/administration & dosage , Aorta/drug effects , Calcium/metabolism , Calmodulin-Binding Proteins/chemistry , Cell Differentiation , Cell Movement , Cell Proliferation , Cells, Cultured , DNA/chemistry , Humans , MAP Kinase Signaling System , Muscle, Smooth, Vascular/drug effects , Nicotine/chemistry , Phenotype , Receptors, G-Protein-Coupled/metabolism , Receptors, Nicotinic/metabolism , Smoking/adverse effects , Transforming Growth Factor beta/metabolism , Tunica Media/pathology
6.
J Biochem ; 152(2): 185-90, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22648562

ABSTRACT

We successfully synthesized full-length and the mutant Physarum myosin and heavy meromyosin (HMM) constructs associated with Physarum regulatory light chain and essential light chain (PhELC) using Physarum myosin heavy chain in Sf-9 cells, and examined their Ca(2+)-mediated regulation. Ca(2+) inhibited the motility and ATPase activities of Physarum myosin and HMM. The Ca(2+) effect is also reversible at the in vitro motility of Physarum myosin. We demonstrated that full-length myosin increases the Ca(2+) inhibition more effectively than HMM. Furthermore, Ca(2+) did not affect the motility and ATPase activities of the mutant Physarum myosin with PhELC that lost Ca(2+)-binding ability. Therefore, we conclude that PhELC plays a critical role in Ca(2+)-dependent regulation of Physarum myosin.


Subject(s)
Calcium/metabolism , Myosins/metabolism , Physarum/metabolism , Animals , Calcium/pharmacology , Cells, Cultured , Mutation , Myosin Light Chains/genetics , Myosin Light Chains/metabolism , Myosin Subfragments/genetics , Myosin Subfragments/metabolism , Myosins/genetics , Physarum/drug effects , Physarum/genetics , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism
7.
J Pharmacol Sci ; 119(1): 91-6, 2012.
Article in English | MEDLINE | ID: mdl-22510518

ABSTRACT

Myosin light-chain kinase (MLCK) is a multi-domain protein with kinase and actin-binding domains, among others. Deficiency of MLCK expression in GBaSM-4 vascular smooth muscle cells enhanced cell proliferation rate and shortened cell doubling time. Transient transfection of the MLCK-deficient cells with cDNA constructs of either wild-type MLCK or its mutant lacking the kinase activity reverted the cell proliferation rate to that of wild-type cells, whereas that of MLCK lacking the actin-binding domain maintained cell proliferation at an elevated rate similar to the MLCK-deficient cells. Thus, the actin-binding domain of MLCK seems to play a role in regulating cell proliferation.


Subject(s)
Actins/metabolism , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/metabolism , Myosin-Light-Chain Kinase/genetics , Actins/genetics , Animals , Cell Line , Cell Proliferation , Down-Regulation , Guinea Pigs , Myosin-Light-Chain Kinase/metabolism , Phosphorylation , Protein Binding , Protein Structure, Tertiary , Rabbits
8.
J Pharmacol Sci ; 116(1): 116-27, 2011.
Article in English | MEDLINE | ID: mdl-21551973

ABSTRACT

Previous work has suggested that in addition to its kinase activity, myosin light chain kinase (MLCK) exhibits non-kinase properties within its N-terminus that could influence cytoskeletal organization of smooth muscle cells (A. Nakamura et al. Biochem Biophys Res Commun. 2008;369:135-143). Myosin ATPase activity measurements indicate that the 26-41 peptide of MLCK significantly decreases ATPase activity as the concentration of this peptide increases. Sliding velocity of actin-filaments on myosin and stress responses in skinned smooth muscle tissue are also inhibited. Peptide-mediated uptake and the microinjection technique in cells indicate that the peptide was necessary for actin-filament stabilization. Fluorescence resonance energy transfer analysis indicated that in the presence of MLCK, α-actin but not ß-actin remodeled during phorbol 12,13-dibutyrate (PDBu)-induced contractions. PDBu also induced podosomes in the cell. When MLCK expression was down-regulated by introduction of RNAi for MLCK by lentivirus vector into the cells, we failed to observe the podosome induction upon PDBu stimulation. Rescue experiments indicate that the non-kinase activity of MLCK plays an important role in maintaining actin stress fibers and in the PDBu-induced reorganization of actin-filaments in smooth muscle cells.


Subject(s)
Actins/metabolism , Cytoskeleton/metabolism , Muscle Contraction/drug effects , Muscle, Smooth/metabolism , Myosin-Light-Chain Kinase/metabolism , Phorbol 12,13-Dibutyrate/pharmacology , Animals , Cell Line , Cell Surface Extensions/drug effects , Cell Surface Extensions/metabolism , Cell Surface Extensions/ultrastructure , Chickens , Cytoskeleton/drug effects , Enzyme Inhibitors/metabolism , Gene Silencing , Guinea Pigs , In Vitro Techniques , Kinetics , Microfilament Proteins/antagonists & inhibitors , Microfilament Proteins/genetics , Microfilament Proteins/metabolism , Muscle, Smooth/drug effects , Muscle, Smooth/ultrastructure , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/metabolism , Myocytes, Smooth Muscle/ultrastructure , Myosin-Light-Chain Kinase/antagonists & inhibitors , Myosin-Light-Chain Kinase/genetics , Myosins/antagonists & inhibitors , Peptide Fragments/metabolism , Phosphorylation/drug effects , Protein Isoforms/antagonists & inhibitors , Protein Isoforms/genetics , Protein Isoforms/metabolism , Protein Processing, Post-Translational/drug effects , RNA, Small Interfering , Rats
9.
J Pharmacol Sci ; 115(4): 532-5, 2011.
Article in English | MEDLINE | ID: mdl-21422730

ABSTRACT

Cigarette smoking is one of the factors causing accumulation of vascular smooth muscle cells (VSMCs) in atherosclerotic plaques. Changes in cell migration toward platelet-derived growth factor BB were investigated using a Boyden chamber after 48-h preincubation of GBaSM-4 VSMCs with nicotine or nicotine-free cigarette smoke extract (CSE). A nicotine concentration of 0.1 µM maximally promoted cell migration; 0.1% CSE also promoted cell migration, while high CSE concentrations damaged GBaSM-4 cells. Fetal bovine serum (FBS) long-depletion induced decrease in migration of GBaSM-4 cells. Our results suggest that nicotine and some CSE components can induce GBaSM-4 cell migration.


Subject(s)
Cell Movement/drug effects , Muscle, Smooth, Vascular/drug effects , Myocytes, Smooth Muscle/physiology , Nicotiana/adverse effects , Nicotine/pharmacology , Platelet-Derived Growth Factor/physiology , Smoke/adverse effects , Animals , Becaplermin , Cell Line , Cell Migration Assays/methods , Cell Movement/physiology , Cell Survival/drug effects , Chemotaxis/drug effects , Guinea Pigs , Myocytes, Smooth Muscle/drug effects , Proto-Oncogene Proteins c-sis
10.
FEBS Lett ; 584(15): 3486-91, 2010 Aug 04.
Article in English | MEDLINE | ID: mdl-20633559

ABSTRACT

To examine the role of two light chains (LCs) of the myosin II on Ca2+ regulation, we produced hybrid heavy meromyosin (HMM) having LCs from Physarum and/or scallop myosin using the smooth muscle myosin heavy chain. Ca2+ inhibited motility and ATPase activity of hybrid HMMs with LCs from Physarum myosin but activated those of hybrid HMM with LCs from scallop myosin, indicating an active role of LCs. ATPase activity of hybrid HMMs with LCs from different species showed the same effect by Ca2+ even though they did not support motility. Our results suggest that communication between the original combinations of LC is important for the motor function.


Subject(s)
Calcium/pharmacology , Myosin Light Chains/metabolism , Myosin Subfragments/metabolism , Pectinidae/enzymology , Physarum/enzymology , Smooth Muscle Myosins/metabolism , Actin Cytoskeleton/drug effects , Actin Cytoskeleton/metabolism , Animals , Enzyme Activation/drug effects , Pectinidae/drug effects , Physarum/drug effects , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Smooth Muscle Myosins/isolation & purification
11.
Am J Physiol Cell Physiol ; 298(5): C1118-26, 2010 May.
Article in English | MEDLINE | ID: mdl-20164381

ABSTRACT

To explore the precise mechanisms of the inhibitory effects of blebbistatin, a potent inhibitor of myosin II, on smooth muscle contraction, we studied the blebbistatin effects on the mechanical properties and the structure of contractile filaments of skinned (cell membrane permeabilized) preparations from guinea pig taenia cecum. Blebbistatin at 10 microM or higher suppressed Ca(2+)-induced tension development at any given Ca(2+) concentration but had little effects on the Ca(2+)-induced myosin light chain phosphorylation. Blebbistatin also suppressed the 10 and 2.75 mM Mg(2+)-induced, "myosin light chain phosphorylation-independent" tension development at more than 10 microM. Furthermore, blebbistatin induced conformational change of smooth muscle myosin (SMM) and disrupted arrangement of SMM and thin filaments, resulting in inhibition of actin-SMM interaction irrespective of activation with Ca(2+). In addition, blebbistatin partially inhibited Mg(2+)-ATPase activity of native actomyosin from guinea pig taenia cecum at around 10 microM. These results suggested that blebbistatin suppressed skinned smooth muscle contraction through disruption of structure of SMM by the agent.


Subject(s)
Cecum/drug effects , Heterocyclic Compounds, 4 or More Rings/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth/drug effects , Myosin Type II/antagonists & inhibitors , Actin Cytoskeleton , Actins/metabolism , Animals , Calcium/pharmacology , Cecum/physiology , Fluorescence Resonance Energy Transfer , Guinea Pigs , Magnesium/pharmacology , Male , Protein Transport , Smooth Muscle Myosins/metabolism
12.
Am J Physiol Heart Circ Physiol ; 298(2): H505-14, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19933418

ABSTRACT

We have been searching for a mechanism to induce smooth muscle contraction that is not associated with phosphorylation of the regulatory light chain (RLC) of smooth muscle myosin (Nakamura A, Xie C, Zhang Y, Gao Y, Wang HH, Ye LH, Kishi H, Okagaki T, Yoshiyama S, Hayakawa K, Ishikawa R, Kohama K. Biochem Biophys Res Commun 369: 135-143, 2008). In this article, we report that arachidonic acid (AA) stimulates ATPase activity of unphosphorylated smooth muscle myosin with maximal stimulation (R(max)) of 6.84 +/- 0.51 relative to stimulation by the vehicle and with a half-maximal effective concentration (EC(50)) of 50.3 +/- 4.2 microM. In the presence of actin, R(max) was 1.72 +/- 0.08 and EC(50) was 26.3 +/- 2.3 microM. Our experiments with eicosanoids consisting of the AA cascade suggested that they neither stimulated nor inhibited the activity. Under conditions that did not allow RLC to be phosphorylated, AA stimulated contraction of smooth muscle tissue with an R(max) of 1.45 +/- 0.07 and an EC(50) of 27.0 +/- 4.4 microM. In addition to the ATPase activities of the myosin, AA stimulated those of heavy meromyosin, subfragment 1 (S1), S1 from which the RLC was removed, and a recombinant heavy chain consisting of the myosin head. The stimulatory effects of AA on these preparations were about twofold. The site of AA action was indicated to be the step-releasing inorganic phosphate (P(i)) from the reaction intermediate of the myosin-ADP-P(i) complex. The enhancement of P(i) release by AA was supported by computer simulation indicating that AA docked in the actin-binding cleft of the myosin motor domain. The stimulatory effect of AA was detectable with both unphosphorylated myosin and the myosin in which RLC was fully phosphorylated. The AA effect on both myosin forms was suggested to cause excess contraction such as vasospasm.


Subject(s)
Arachidonic Acid/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth/enzymology , Myosins/metabolism , Smooth Muscle Myosins/metabolism , Animals , Computer Simulation , Guinea Pigs , Male , Models, Animal , Muscle Contraction/physiology , Muscle, Smooth/drug effects , Myosins/drug effects , Phosphates/metabolism , Phosphorylation , Smooth Muscle Myosins/ultrastructure
13.
Cell Biol Int ; 34(1): 35-40, 2009 Dec 16.
Article in English | MEDLINE | ID: mdl-19947949

ABSTRACT

The plasmodium Physarum polycephalum exhibits periodic cycles of cytoplasmic streaming in association with those of contraction and relaxation movement. In the present study, we injected Calcium Green dextran as a fluorescent Ca2+ indicator into the thin-spread living plasmodium. We found changes in the [Ca2+]i (intracellular concentration of Ca2+), which propagated in a wave-like form in its cytoplasm. The Ca2+ waves were also detected when we used Fura dextran which detected [Ca2+]i by the ratio of two wavelengths. We prepared the plasmodial fragment from the thin-spread and found that the cycles of the contraction-relaxation movement was so synchronized that the measurement of its area provided an indication of the movement. We observed that [Ca2+]i also synchronized in the entire fragment and that the relaxation ensued upon the reduction in [Ca2+]i. We suggest that the Ca2+ wave generated periodically is one of the major factors playing a crucial role in the relaxation of P. polycephalum.


Subject(s)
Calcium/metabolism , Cytoplasmic Streaming , Physarum polycephalum/physiology , Calcium Signaling , Dextrans/pharmacology , Fluorescent Dyes/pharmacology , Movement , Organic Chemicals/pharmacology , Periodicity , Physarum polycephalum/metabolism
14.
IUBMB Life ; 61(11): 1092-8, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19859981

ABSTRACT

Myosin light-chain kinase (MLCK) comprised of N-terminal actin-binding domain, central catalytic domain, and C-terminal myosin-binding domain. It exerted not only kinase activity to phosphorylate 20 kDa regulatory light chain of smooth muscle but also exerted non-kinase activity on myosin motor and myosin ATPase activities (Nakamura et al., Biochem. Biophys. Res. Commun. 2008, 369, 135). The previous studies on the multiple MLCK functions were done using MLCK fragments. The present study reported the expression of whole MLCK molecules in Escherichia coli in a large amount. The construct in which the calmodulin (CaM) binding domain for regulating kinase activity was mutated lost the kinase activity. However, the mutant exerted non-kinase activity and inhibited both myosin motor and ATPase activities. The domain that regulated kinase activity was also shown to be involved in the Ca(2+) regulation of non-kinase activity. The deletion mutants of actin-binding domain which located at N-terminal 1-41 amino acids demonstrated that non-kinase activity was mediated through actin filaments.


Subject(s)
Calcium/metabolism , Myosin-Light-Chain Kinase/metabolism , Actins/physiology , Binding Sites , Calcium-Binding Proteins/metabolism , Catalytic Domain , Escherichia coli/enzymology , Mutation , Myosin Light Chains/metabolism , Myosin-Light-Chain Kinase/drug effects , Myosin-Light-Chain Kinase/genetics , Myosins/metabolism , Protein Structure, Tertiary , Recombinant Proteins/drug effects , Recombinant Proteins/metabolism
15.
Am J Physiol Heart Circ Physiol ; 296(5): H1683-93, 2009 May.
Article in English | MEDLINE | ID: mdl-19234090

ABSTRACT

The actin-myosin interaction of vascular smooth muscle cells (VSMCs) is regulated by myosin light chain kinase (MLCK), which is a fusion protein of the central catalytic domain with the N-terminal actin-binding and C-terminal myosin-binding domains. In addition to the regulatory role of kinase activity mediated by the catalytic domain, nonkinase activity that derives from both terminals is able to exert a regulatory role as reviewed by Nakamura et al. (32). We previously showed that nonkinase activity mediated the filopodia upon the stimulation by sphingosylphosphorylcholine (SPC) (25). To explore the regulatory role of nonkinase activity in chemotaxis, we constructed VSMCs where the expression of MLCK was totally abolished by using a lentivirus-mediated RNAi system. We hypothesized that the MLCK-downregulated VSMCs were unable to form filopodia and to migrate upon SPC stimulation and confirmed the hypothesis. We further constructed a kinase-inactive mutant from bovine cDNA coding wild-type (WT) MLCK by mutating the ATP-binding sites located in the catalytic domain, followed by confirming the presence (absence) of the kinase activity of WT (kinase-inactive mutant). We transfected WT and the mutant into MLCK-downregulated VSMCs. We expected that the transfected VSMCs will recover the ability to induce filopodia and chemotaxis toward SPC and found both constructs rescued the ability. Because they share the actin- and myosin-binding domains, we concluded nonkinase activity plays a major role for SPC-induced migration.


Subject(s)
Chemotaxis , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/metabolism , Myosin-Light-Chain Kinase/metabolism , Phosphorylcholine/analogs & derivatives , Pseudopodia/metabolism , Sphingosine/analogs & derivatives , Actins/metabolism , Animals , Binding Sites , Cattle , Cell Line , Chemotaxis/drug effects , Guinea Pigs , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/enzymology , Mutation , Myocytes, Smooth Muscle/drug effects , Myocytes, Smooth Muscle/enzymology , Myosin Type II/metabolism , Myosin-Light-Chain Kinase/genetics , Phosphorylcholine/metabolism , Protein Kinase Inhibitors/pharmacology , Pseudopodia/drug effects , RNA Interference , RNA, Small Interfering/metabolism , Rats , Sphingosine/metabolism , Transfection , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors , p38 Mitogen-Activated Protein Kinases/metabolism , rho-Associated Kinases/antagonists & inhibitors , rho-Associated Kinases/metabolism
16.
Biochem Biophys Res Commun ; 369(1): 135-43, 2008 Apr 25.
Article in English | MEDLINE | ID: mdl-18053800

ABSTRACT

Myosin light-chain kinase (MLCK) of smooth muscle consists of an actin-binding domain at the N-terminal, the catalytic domain in the central portion, and the myosin-binding domain at the C-terminal. The kinase activity is mediated by the catalytic domain that phosphorylates the myosin light-chain of 20kDa (MLC20), activating smooth muscle myosin to interact with actin. Although the regulatory role of the kinase activity is well established, the role of non-kinase activity derived from actin-binding and myosin-binding domains remains unknown. This review is dedicated to Dr. Setsuro Ebashi, who devoted himself to elucidating the non-kinase activity of MLCK after establishing calcium regulation through troponin in skeletal and cardiac muscles. He proposed that the actin-myosin interaction of smooth muscle could be activated by the non-kinase activity of MLCK, a mechanism that is quite independent of MLC20 phosphorylation. The authors will extend his proposal for the role of non-kinase activity. In this review, we express MLCK and its fragments as recombinant proteins to examine their effects on the actin-myosin interaction in vitro. We also down-regulate MLCK in the cultured smooth muscle cells, and propose that MLC20 phosphorylation is not obligatory for the smooth muscle to contract.


Subject(s)
Actins/physiology , Calcium Signaling/physiology , Models, Biological , Muscle Contraction/physiology , Muscle, Smooth/physiology , Myosin-Light-Chain Kinase/physiology , Animals , Enzyme Activation , Feedback/physiology , Humans
17.
J Pharmacol Sci ; 102(3): 339-42, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17072099

ABSTRACT

We prepared a cell-populated collagen-gel fiber including GbaSM-4 cells derived from the basilar artery of guinea pigs. This fiber tended to be a differentiated contractile phenotype in electron-microscope observations. Sphingosylphosphorylcholine (SPC) can induce contraction of the fiber (EC50 = 0.70 +/- 0.05 microM), and blebbistatin can inhibit the SPC-induced contraction (IC50 = 22.8 +/- 1.26 microM). Phosphorylation of the 20 kD myosin light chain (MLC20) significantly increased in GbaSM-4 cells provided with 1 microM SPC (P<0.05), which was maintained in the presence of 1 to 100 microM blebbistatin. These results suggest that vascular smooth muscle can relax even if MLC20 is phosphorylated.


Subject(s)
Collagen/chemistry , Heterocyclic Compounds, 4 or More Rings/pharmacology , Muscle, Smooth, Vascular/drug effects , Phosphorylcholine/analogs & derivatives , Sphingosine/analogs & derivatives , Animals , Cells, Cultured , Gels , Guinea Pigs , Microscopy, Electron , Muscle Contraction/drug effects , Myosin Light Chains/metabolism , Phosphorylcholine/antagonists & inhibitors , Phosphorylcholine/pharmacology , Sphingosine/antagonists & inhibitors , Sphingosine/pharmacology
18.
Am J Physiol Heart Circ Physiol ; 291(3): H1262-72, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16899767

ABSTRACT

Molecular mechanisms underlying migration of vascular smooth muscle cells (VSMCs) toward sphingosylphosphorylcholine (SPC) were analyzed in light of the hypothesis that remodeling of the actin cytoskeleton should be involved. After SPC stimulation, mitogen-activated protein kinases (MAPKs), including p38 MAPK (p38) and p42/44 MAPK (p42/44), were found to be phosphorylated. Migration of cells toward SPC was reduced in the presence of SB-203580, an inhibitor of p38, but not PD-98059, an inhibitor of p42/44. Pertussis toxin (PTX), a Gi protein inhibitor, induced an inhibitory effect on p38 phosphorylation and VSMC migration. Myosin light chain (MLC) phosphorylation occurred after SPC stimulation with or without pretreatment with SB-203580 or PTX. The MLC kinase inhibitor ML-7 and the Rho kinase inhibitor Y-27632 inhibited MLC phosphorylation but only partially inhibited SPC-directed migration. Complete inhibition was achieved with the addition of SB-203580. After SPC stimulation, the actin cytoskeleton formed thick bundles of actin filaments around the periphery of cells, and the cells were surrounded by elongated filopodia, i.e., magunapodia. The peripheral actin bundles consisted of alpha- and beta-actin, but magunapodia consisted exclusively of beta-actin. Such a remodeling of actin was reversed by addition of SB-203580 and PTX, but not ML-7 or Y-27632. Taken together, our biochemical and morphological data confirmed the regulation of actin remodeling and suggest that VSMCs migrate toward SPC, not only by an MLC phosphorylation-dependent pathway, but also by an MLC phosphorylation-independent pathway.


Subject(s)
Actins/drug effects , Cell Movement/drug effects , Muscle, Smooth, Vascular/drug effects , Phosphorylcholine/analogs & derivatives , Signal Transduction/drug effects , Sphingosine/analogs & derivatives , Actins/metabolism , Actins/ultrastructure , Amides/pharmacology , Animals , Azepines/pharmacology , Cell Movement/physiology , Cells, Cultured , Cytoskeleton/metabolism , Cytoskeleton/ultrastructure , Enzyme Inhibitors/pharmacology , GTP-Binding Proteins/physiology , Guinea Pigs , Imidazoles/pharmacology , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase Kinases/metabolism , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/metabolism , Myosin Light Chains/metabolism , Myosin Light Chains/physiology , Naphthalenes/pharmacology , Pertussis Toxin/pharmacology , Phosphorylation/drug effects , Phosphorylcholine/pharmacology , Pyridines/pharmacology , Signal Transduction/physiology , Sphingosine/pharmacology , p38 Mitogen-Activated Protein Kinases/metabolism
19.
Biochem Biophys Res Commun ; 305(1): 16-21, 2003 May 23.
Article in English | MEDLINE | ID: mdl-12732190

ABSTRACT

Myosin light chain kinase (MLCK) is a multifunctional regulatory protein of smooth muscle contraction [IUBMB Life 51 (2001) 337, for review]. The well-established mode for its regulation is to phosphorylate the 20 kDa myosin light chain (MLC 20) to activate myosin ATPase activity. MLCK exhibits myosin-binding activity in addition to this kinase activity. The myosin-binding activity also stimulates myosin ATPase activity without phosphorylating MLC 20 [Proc. Natl. Acad. Sci. USA 96 (1999) 6666]. We engineered an MLCK fragment containing the myosin-binding domain but devoid of a catalytic domain to explore how myosin is stimulated by this non-kinase pathway. The recombinant fragment thus obtained stimulated myosin ATPase activity by V(max)=5.53+/-0.63-fold with K(m)=4.22+/-0.58 microM (n=4). Similar stimulation figures were obtained by measuring the ATPase activity of HMM and S1. Binding of the fragment to both HMM and S1 was also verified, indicating that the fragment exerts stimulation through the myosin heads. Since S1 is in an active form regardless of the phosphorylated state of MLC 20, we conclude that the non-kinase stimulation is independent of the phosphorylating mode for activation of myosin.


Subject(s)
Myosin-Light-Chain Kinase/metabolism , Smooth Muscle Myosins/chemistry , Smooth Muscle Myosins/metabolism , Binding Sites , Enzyme Activation , Glutathione Transferase/genetics , Myosin Light Chains/metabolism , Myosin Subfragments , Myosin-Light-Chain Kinase/genetics , Phosphorylation , Recombinant Fusion Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...